AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27012243 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney growth (secondary outcome)
Number of subjects: 450
Study 27012243 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (secondary outcome)
Number of subjects: 450
Study 27012629 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (3600mg/day EPA/DHA for 6 weeks)
Number of subjects: 14
Study 27012629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27012891 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary inferior vena cava (IVC) filters
Number of subjects: 0
Study 27012891 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available IVC filters (both temporary and permanent)
Number of subjects: 0
Study 27013022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 92
Study 27013022 — intervention group
Group type: COMPARATOR
Intervention: Non-Dexamethasone (N-DXM)
Number of subjects: 92
Study 27013155 — intervention group
Group type: EXPERIMENTAL
Intervention: DESolve novolimus-eluting bioresorbable coronary scaffold
Number of subjects: 126
Study 27013162 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27013249 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution two-dimensional (2D) speckle tracking echocardiography (STE)
Number of subjects: 47
Study 27013249 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature tracking echocardiography (FT-E)
Number of subjects: 47
Study 27013249 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature tracking cardiac magnetic resonance imaging (FT-CMR)
Number of subjects: 47
Study 27013249 — intervention group
Group type: COMPARATOR
Intervention: Ejection fraction (EF)
Number of subjects: 47
Study 27013512 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly follow-up without treatment of asymptomatic mono or mixed P. falciparum infections (24 participants)
Number of subjects: 1447
Study 27013512 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with P. vivax mono-infection (34 participants)
Number of subjects: 1447
Study 27014033 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond-based electrodes
Number of subjects: 4
Study 27014033 — intervention group
Group type: COMPARATOR
Intervention: Carbon fiber electrodes
Number of subjects: 4
Study 27015087 — intervention group
Group type: EXPERIMENTAL
Intervention: Armolipid Plus (AP) supplementation
Number of subjects: 102
Study 27015087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 27015233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU Mobility Scale (IMS) at ICU discharge
Number of subjects: 192
Study 27015233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU Mobility Scale (IMS) from study enrollment to ICU discharge
Number of subjects: 192
Study 27015392 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling tunneled pleural catheters (ITPCs)
Number of subjects: 24
Study 27015562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed + Sorafenib
Number of subjects: 33
Study 27015562 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of ERBB1/2/4
Number of subjects: 33
Study 27015562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib or Vandetanib (5 day transient exposure)
Number of subjects: 33
Study 27015562 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (ERBB1/2/4 inhibitor)
Number of subjects: 33
Study 27015798 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (EART) based on lopinavir/r
Number of subjects: 217
Study 27015798 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (non-inclusion reasons)
Number of subjects: 217
Study 27015798 — intervention group
Group type: EXPERIMENTAL
Intervention: EART initiation
Number of subjects: 217
Study 27015798 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of HIV status to father
Number of subjects: 217
Study 27015798 — intervention group
Group type: EXPERIMENTAL
Intervention: Age older than 12 months
Number of subjects: 217
Study 27016248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 112
Study 27016248 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulties in Emotion Regulation Questionnaire
Number of subjects: 112
Study 27016248 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Anxiety Inventory
Number of subjects: 112
Study 27016248 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Control Scale
Number of subjects: 112
Study 27016248 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental computer-based attentional control task
Number of subjects: 112
Study 27018175 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg
Number of subjects: 492
Study 27018175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492
Study 27018703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin Ointment
Number of subjects: 0
Study 27018703 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27018841 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+
Number of subjects: 92
Study 27018988 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a/ribavirin for 48 weeks
Number of subjects: 3181
Study 27019674 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients during exercise echocardiography and cardiopulmonary exercise testing (CPET)
Number of subjects: 27
Study 27019674 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients at rest
Number of subjects: 27
Study 27019674 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients at peak exercise
Number of subjects: 27
Study 27019674 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 27
Study 27019674 — intervention group
Group type: COMPARATOR
Intervention: Non-COPD subjects (controls) at rest
Number of subjects: 27
Study 27019674 — intervention group
Group type: COMPARATOR
Intervention: Non-COPD subjects (controls) at peak exercise
Number of subjects: 27
Study 27019745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training application
Number of subjects: 0
Study 27019745 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy application
Number of subjects: 0
Study 27019745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-sensing application promoting daily activities
Number of subjects: 0
Study 27019745 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27020111 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy (RT) - 25 Gy in 5 daily intensity modulated RT fractions over 1 week
Number of subjects: 32
Study 27020720 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 316
Study 27021379 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (ABMNC) therapy
Number of subjects: 21
Study 27021538 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% chlorhexidine (CHX) gel applied using individual trays (3DS)
Number of subjects: 20
Study 27021538 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% chlorhexidine (CHX) gel
Number of subjects: 20
Study 27021538 — intervention group
Group type: COMPARATOR
Intervention: untreated brackets
Number of subjects: 20
Study 27021967 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (mean dose 195.6 ± 154.8 mg/day)
Number of subjects: 665
Study 27022067 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatorsen (OGX-427) administered i.v. weekly in 21-day cycles following 3 loading doses and over 5 dose levels (200-1000 mg)
Number of subjects: 42
Study 27022067 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatorsen (OGX-427)
Number of subjects: 42
Study 27022477 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial retinotomy with endodiathermy
Number of subjects: 9
Study 27022956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (71 caregivers)
Number of subjects: 153
Study 27022956 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 153
Study 27025160 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg/d on days 1-14) plus bortezomib (1.3 mg/m² intravenously on days 1, 4, 8, and 11)
Number of subjects: 0
Study 27025160 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 0
Study 27025399 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise intervention (treatment education adherence intervention) consisting of 6-10 individual counseling sessions over 6 months.
Number of subjects: 0
Study 27025399 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) for 6 months.
Number of subjects: 0
Study 27025436 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter interatrial shunt device (IASD)
Number of subjects: 68
Study 27025608 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-6063 (defactinib, PF-04554878) 200 mg BID
Number of subjects: 9
Study 27025608 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-6063 (defactinib, PF-04554878) 400 mg BID (RP2D)
Number of subjects: 9
Study 27025608 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-6063 (defactinib, PF-04554878) 200-600 mg BID
Number of subjects: 9
Study 27025608 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-6063 (defactinib, PF-04554878)
Number of subjects: 9
Study 27025825 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyme disease patients (natural history study)
Number of subjects: 101
Study 27026379 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal vein thrombosis (PVT) patients (n=126; 17% prevalence)
Number of subjects: 753
Study 27026379 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous portal vein thrombosis
Number of subjects: 753
Study 27026379 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Child-Pugh Class B+C
Number of subjects: 753
Study 27026379 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hepatocellular carcinoma
Number of subjects: 753
Study 27026379 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous upper gastrointestinal bleeding
Number of subjects: 753
Study 27026379 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 753
Study 27026379 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with portal vein thrombosis not treated with anticoagulant therapy
Number of subjects: 753
Study 27027250 — intervention group
Group type: EXPERIMENTAL
Intervention: Translated Gene Expression Profiling (GEP) risk signatures
Number of subjects: 126
Study 27028025 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic control (mean HbA1c)
Number of subjects: 64
Study 27028025 — intervention group
Group type: COMPARATOR
Intervention: Adjusted clinical covariates (age, DCCT cohort assignment, DCCT treatment arm, BMI, insulin dosage, parity, hysterectomy, autonomic neuropathy, urinary tract infection in the last year)
Number of subjects: 64
Study 27028469 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient report
Number of subjects: 1578
Study 27028469 — intervention group
Group type: COMPARATOR
Intervention: Automated chart review
Number of subjects: 1578
Study 27028469 — intervention group
Group type: COMPARATOR
Intervention: Manual chart review
Number of subjects: 1578
Study 27028666 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic gastrostomy tube (PGT)
Number of subjects: 95
Study 27028666 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counselling with a therapeutic feeding tube if required (Control)
Number of subjects: 95
Study 27028666 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (FACT-H&N score)
Number of subjects: 95
Study 27029034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50mg) therapy for 3 cycles
Number of subjects: 14
Study 27029034 — intervention group
Group type: COMPARATOR
Intervention: Untreated biopsy samples
Number of subjects: 14
Study 27029034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrectomy samples after sunitinib treatment
Number of subjects: 14
Study 27029034 — intervention group
Group type: COMPARATOR
Intervention: Renal artery ligation
Number of subjects: 14
Study 27029228 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine (90 mg/m² on days 1 and 2) plus Rituximab (375 mg/m² on day 1), every 4 weeks.
Number of subjects: 60
Study 27029228 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus Rituximab (as described above)
Number of subjects: 60
Study 27029399 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital GIS data implementation in the ED
Number of subjects: 599
Study 27029399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' perceptions regarding patient reception, workflow, and resource utilization
Number of subjects: 599
Study 27029399 — intervention group
Group type: COMPARATOR
Intervention: Comparison with control period (no GIS data)
Number of subjects: 599
Study 27029636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide and Valproic Acid
Number of subjects: 445
Study 27029636 — intervention group
Group type: COMPARATOR
Intervention: NHANES controls
Number of subjects: 445
Study 27029940 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phytic acid beans (lpa)
Number of subjects: 25
Study 27029940 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-biofortified beans (BBs)
Number of subjects: 25
Study 27029940 — intervention group
Group type: COMPARATOR
Intervention: Control beans (CBs)
Number of subjects: 25
Study 27030066 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg once daily)
Number of subjects: 655
Study 27030066 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin and vitamin K antagonist (1.0 mg/kg twice daily and warfarin or acenocoumarol; INR 2.0-3.0)
Number of subjects: 655
Study 27030066 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 655
Study 27030066 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin and vitamin K antagonist
Number of subjects: 655
Study 27030277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ziv-aflibercept (1.25 mg/0.05 mL)
Number of subjects: 30
Study 27030279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment
Number of subjects: 1695
Study 27030531 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing dietary pulses (median intake of 132 g/d or ∼1 serving/d)
Number of subjects: 940
Study 27030531 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched negative-energy-balance diets
Number of subjects: 940
Study 27030531 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral-energy-balance diets
Number of subjects: 940
Study 27030531 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing dietary pulses
Number of subjects: 940
Study 27030536 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk samples from healthy lactating women
Number of subjects: 41
Study 27030536 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine samples from healthy lactating women
Number of subjects: 41
Study 27030536 — intervention group
Group type: COMPARATOR
Intervention: Comparison of urine concentrations between subjects consuming organic vs conventionally grown foods
Number of subjects: 41
Study 27030536 — intervention group
Group type: COMPARATOR
Intervention: Comparison of urine concentrations between women living on or near a farm/ranch vs urban/suburban areas
Number of subjects: 41
Study 27031231 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine (ASAQ)
Number of subjects: 0
Study 27031231 — intervention group
Group type: COMPARATOR
Intervention: Artemether-Lumefantrine (AL)
Number of subjects: 0
Study 27031231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ASAQ and AL
Number of subjects: 0
Study 27032057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu IUD
Number of subjects: 548
Study 27032057 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral LNG
Number of subjects: 548
Study 27032301 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus neoadjuvant chemotherapy (intravenous fluorouracil 500 mg/m², epirubicin 100 mg/m², cyclophosphamide 500 mg/m², and bevacizumab 15 mg/kg during cycles 1-4; docetaxel 100 mg/m² and bevacizumab during cycles 5-8)
Number of subjects: 100
Study 27032301 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (adjuvant)
Number of subjects: 100
Study 27032301 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (without bevacizumab)
Number of subjects: 100
Study 27032301 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 100
Study 27033025 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg/d
Number of subjects: 0
Study 27033025 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/d
Number of subjects: 0
Study 27033025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27033062 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 66
Study 27033711 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolised colistin (AS) - 4 million units by nebulisation three times per 24 hours
Number of subjects: 149
Study 27033958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical administration of hyaluronic acid and chondroitin sulfate (HA+CS)
Number of subjects: 276
Study 27033958 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (antimicrobial/immunoactive prophylaxis/probiotics/cranberry)
Number of subjects: 276
Study 27034426 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use in the last month
Number of subjects: 175
Study 27034426 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with lower odds of consistent condom use
Number of subjects: 175
Study 27034426 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with higher likelihood of consistent condom use
Number of subjects: 175
Study 27034453 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infection with MetS
Number of subjects: 301
Study 27034453 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infection without MetS
Number of subjects: 301
Study 27034453 — intervention group
Group type: COMPARATOR
Intervention: General population (Framingham cohort)
Number of subjects: 301
Study 27034453 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HIV-1 infection
Number of subjects: 301
Study 27034453 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 301
Study 27034453 — intervention group
Group type: EXPERIMENTAL
Intervention: MetS
Number of subjects: 301
Study 27035377 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 455
Study 27035377 — intervention group
Group type: COMPARATOR
Intervention: Anemia group
Number of subjects: 455
Study 27035377 — intervention group
Group type: COMPARATOR
Intervention: Non-anemia group
Number of subjects: 455
Study 27035632 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS) score ≥ 6 at admission
Number of subjects: 306
Study 27035632 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS) score ≥ 6 at 6 months
Number of subjects: 306
Study 27035632 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher GDS score at 6 months
Number of subjects: 306
Study 27036160 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (3 mg/m² IV on day 1), all-trans retinoic acid (45 mg/m² orally on days 4-6 and 15 mg/m² orally on days 7-28), high-dose cytarabine (3 g/m²/12 h IV on days 1-3), mitoxantrone (12 mg/m² IV on days 2-3)
Number of subjects: 93
Study 27036160 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation
Number of subjects: 93
Study 27036160 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients responding to salvage therapy and undergoing allogeneic hematopoietic cell transplantation
Number of subjects: 93
Study 27036160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation
Number of subjects: 93
Study 27036160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fms-like tyrosine kinase internal tandem duplication positive AML
Number of subjects: 93
Study 27036163 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention integrated into clinical management
Number of subjects: 0
Study 27036163 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 27036994 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of viraemia
Number of subjects: 26503
Study 27036994 — intervention group
Group type: EXPERIMENTAL
Intervention: Aware viral load
Number of subjects: 26503
Study 27036994 — intervention group
Group type: EXPERIMENTAL
Intervention: Population viral load
Number of subjects: 26503
Study 27036994 — intervention group
Group type: EXPERIMENTAL
Intervention: Population ART coverage
Number of subjects: 26503
Study 27036994 — intervention group
Group type: EXPERIMENTAL
Intervention: In-care viral load
Number of subjects: 26503
Study 27037650 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuven Immunomodulatory Protocol (LIP)
Number of subjects: 13
Study 27037664 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy plaque stimulation
Number of subjects: 33
Study 27037664 — intervention group
Group type: EXPERIMENTAL
Intervention: Diseased plaque stimulation
Number of subjects: 33
Study 27037664 — intervention group
Group type: COMPARATOR
Intervention: Whole blood from healthy siblings
Number of subjects: 33
Study 27039126 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration ≥120 ms
Number of subjects: 0
Study 27039126 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 0
Study 27039387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib 3 mg weekly
Number of subjects: 44
Study 27039387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg weekly
Number of subjects: 44
Study 27039387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib 5.5 mg (maximum tolerated dose)
Number of subjects: 44
Study 27039928 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) therapy
Number of subjects: 84
Study 27039928 — intervention group
Group type: COMPARATOR
Intervention: PAP withdrawal
Number of subjects: 84